SNN Launches ALLEVYN COMPLETE CARE Dressing for Wound Management

Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.

Zacks Investment Research • Mar 11, 2026

Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence.

GlobeNewsWire • Mar 10, 2026

Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026

Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.

GlobeNewsWire • Mar 3, 2026

UK medical products maker Smith & Nephew's annual profit jumps 15.5%

British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across its divisions.

Reuters • Mar 2, 2026

Smith & Nephew posts sharp rise in profit and cash flow

Smith+Nephew reported a strong finish to 2025, with profits and cash flow rising as it completed its three-year turnaround plan and set out ambitions for faster growth. Fourth quarter revenue rose 8.3% to $1.7 billion, or 6.2% on an underlying basis, meaning full-year revenue increased 6.1% to $6.2 billion, with underlying growth of 5.3%.

Proactive Investors • Mar 2, 2026

Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript

Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 2, 2026

Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026

Uniting the most advanced technologies for biomechanical repair and biological augmentation  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–40%2 structural failure rates using traditional surgical techniques.

GlobeNewsWire • Mar 2, 2026

Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC™ Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. The system is designed to improve implant integrity and patient comfort1-6—key priorities for surgeons and healthcare systems alike.

GlobeNewsWire • Feb 24, 2026

Smith+Nephew signs distribution agreement with SI-BONE

Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients  Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures.

GlobeNewsWire • Feb 23, 2026

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Feb 23, 2026